Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Yttrium-90 for HCC Resection
NCT03812562Phase 1Terminated
- Sponsor
- Northwestern University
- Start
- Feb 2019
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in hepatocellular carcinoma (HCC), sponsored by Northwestern University. Primary endpoint: Recurrence rate at 3 years. Started Feb 2019; status: terminated.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03812562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03812562.